IL6 and COVID-19: While many trials are still ongoing, a recent meta-analysis revealed, that therapeutic IL-6 (receptor) antagonists are effective in reducing mortality in COVID-19 patients, while the risk of side effects is higher [34], highlighting the potential but also the need for better therapies.